Hui Shao,
Courtesy Assistant Professor
Department:
Pharmaceutical Outcomes & Policy
Business Phone:
(352) 294-8323
Business Email:
hui.shao@ufl.edu
Teaching Profile
Courses Taught
2020-2023
PHA5267 Prin Pharm-Economics
2021-2024
PHA6940 Supervised Teaching
2021-2022
PHA6971 Research for Master’s Thesis
2020-2022
PHA6935 Selected Topics in Pharmacy
2020-2023
PHA6910 Supervised Research
2021-2022
PHA6805 Applied Data Interpretation and Reporting of Findings in Pharmacy
2020-2024
PHA7979 Advanced Research
2021-2023
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I
2021-2024
PHA6936 Advanced Topics in Pharmaceutical Sciences
2021-2024
PHA6937 Topics in Pharmaceutical Administration
2020-2021,2025
PHA7980 Research for Doctoral Dissertation
2019
PHA5878C Pt Care 3: Cv and Pulm
2023
PHA6946 Practicum in the Pharmaceutical Sciences
Publications
Academic Articles
2025
A Responsible Framework for Assessing, Selecting, and Explaining Machine Learning Models in Cardiovascular Disease Outcomes Among People With Type 2 Diabetes: Methodology and Validation Study
JMIR Medical Informatics.
13:e66200-e66200
[DOI] 10.2196/66200.
2025
Capturing the Additional Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists Beyond the Control of Traditional Risk Factors in People With Diabetes.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
28(5):762-768
[DOI] 10.1016/j.jval.2025.01.015.
[PMID] 39922304.
2025
Developing a Computable Phenotype for Identifying Children, Adolescents, and Young Adults With Diabetes Using Electronic Health Records in the DiCAYA Network
Diabetes Care.
48(6):914-921
[DOI] 10.2337/dc24-1972.
[PMID] 40163581.
2025
Developing an automated algorithm for identification of children and adolescents with diabetes using electronic health records from the OneFlorida+ clinical research network
Diabetes, Obesity and Metabolism.
27(1):102-110
[DOI] 10.1111/dom.15987.
[PMID] 39344840.
2025
Heterogeneous effects of sodium–glucose cotransporter‐2 inhibitors compared to dipeptidyl peptidase‐4 inhibitors on nephrolithiasis in older adults with type 2 diabetes
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.
[DOI] 10.1002/phar.70030.
2025
Incidence and Risk Factors of Diagnosed Young-Adult-Onset Type 2 Diabetes in the U.S.: The National Health Interview Survey 2016–2022
Diabetes Care.
48(3):371-380
[DOI] 10.2337/dc24-1699.
2025
Long‐term cost‐effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity
Diabetes, Obesity and Metabolism.
27(8):4288-4299
[DOI] 10.1111/dom.16466.
2025
Long‐term health benefit and economic return of time in range (TIR) improvement in individuals with type 2 diabetes
Diabetes, Obesity and Metabolism.
27(3):1564-1571
[DOI] 10.1111/dom.16168.
[PMID] 39778035.
2025
Racial/Ethnic Disparities in Use of Angiotensin II Receptor Type 2/4 Stimulatory Vs. Inhibitory Antihypertensive Among Hypertensive Adults in the USA.
Journal of racial and ethnic health disparities.
12(3):1375-1384
[DOI] 10.1007/s40615-024-01970-w.
[PMID] 38498117.
2025
Value-Based Pricing and Its Implications for the Newly Announced Medicare Negotiated Price Under the Inflation Reduction Act
Diabetes Care.
48(4):e44-e46
[DOI] 10.2337/dc24-2403.
[PMID] 39841556.
2024
5‐Year simulation of diabetes‐related complications in people treated with tirzepatide or semaglutide versus insulin glargine
Diabetes, Obesity and Metabolism.
26(2):463-472
[DOI] 10.1111/dom.15332.
[PMID] 37867175.
2024
Association between low cognitive performance and diabetes‐related health indicators across racial and ethnic groups in adults with diabetes
Diabetes, Obesity and Metabolism.
26(9):3723-3731
[DOI] 10.1111/dom.15715.
[PMID] 38899435.
2024
Associations Between Postdischarge Care and Cognitive Impairment–Related Hospital Readmissions for Ketoacidosis and Severe Hypoglycemia in Adults With Diabetes
Diabetes Care.
47(2):225-232
[DOI] 10.2337/dca23-0013.
[PMID] 38048487.
2024
Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes.
PloS one.
19(1)
[DOI] 10.1371/journal.pone.0297208.
[PMID] 38285682.
2024
Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.
Annals of internal medicine.
177(8):1004-1015
[DOI] 10.7326/M24-0329.
[PMID] 39008852.
2024
Incremental burden on health‐related quality of life, health service utilization and direct medical expenditures associated with cognitive impairment among non‐institutionalized people with diabetes aged 65 years and older
Diabetes, Obesity and Metabolism.
26(1):275-282
[DOI] 10.1111/dom.15313.
[PMID] 37789596.
2024
Renal function as an effect modifier of intensive glucose control in delaying cognitive function decline among individuals with type 2 diabetes: A revisit to the ACCORD MIND trial
Diabetes, Obesity and Metabolism.
26(9):3958-3968
[DOI] 10.1111/dom.15744.
[PMID] 38962812.
2024
Sodium-glucose cotransporter-2 inhibitors and incidence of atrial fibrillation in older adults with type 2 diabetes: a retrospective cohort analysis.
Frontiers in pharmacology.
15
[DOI] 10.3389/fphar.2024.1379251.
[PMID] 38846094.
2024
Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes
Diabetes, Obesity and Metabolism.
26(12):5727-5736
[DOI] 10.1111/dom.15943.
[PMID] 39256938.
2024
Some patients with type 2 diabetes may benefit from intensive glycaemic and blood pressure control: A post‐hoc machine learning analysis of ACCORD trial data
Diabetes, Obesity and Metabolism.
26(4):1502-1509
[DOI] 10.1111/dom.15453.
[PMID] 38297986.
2024
Trends in utilization patterns of newer glucose-lowering drugs in US adults with type 2 diabetes and a history of coronary heart disease or heart failure: 2005-2019.
Primary care diabetes.
18(5):561-563
[DOI] 10.1016/j.pcd.2024.07.003.
[PMID] 39095227.
2024
Uncertainty-Aware Pre-Trained Foundation Models for Patient Risk Prediction via Gaussian Process
Companion Proceedings of the ACM Web Conference 2024.
1162-1165
[DOI] 10.1145/3589335.3651456.
[PMID] 40041765.
2023
A prediction model on incident chronic kidney disease among individuals with type 2 diabetes in the United States
Diabetes, Obesity and Metabolism.
25(10):2862-2868
[DOI] 10.1111/dom.15177.
2023
Association between first-line antidepressant use and risk of dementia in older adults: a retrospective cohort study.
Research square.
[DOI] 10.21203/rs.3.rs-3266805/v1.
[PMID] 37790299.
2023
Association between first-line antidepressant use and risk of dementia in older adults: a retrospective cohort study.
BMC geriatrics.
23(1)
[DOI] 10.1186/s12877-023-04475-z.
[PMID] 38066473.
2023
Changes in racial and ethnic disparities in glucose‐lowering drug utilization and glycated haemoglobin A1c in US adults with diabetes: 2005‐2018
Diabetes, Obesity and Metabolism.
25(2):516-525
[DOI] 10.1111/dom.14894.
[PMID] 36251173.
2023
Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia.
Journal of managed care & specialty pharmacy.
29(8):884-895
[DOI] 10.18553/jmcp.2023.29.8.884.
[PMID] 37523313.
2023
Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies.
Journal of the American Geriatrics Society.
71(7):2096-2106
[DOI] 10.1111/jgs.18306.
[PMID] 36821780.
2023
Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample
Annals of Internal Medicine.
176(4):582-583
[DOI] 10.7326/m22-3051.
2023
The role of health system penetration rate in estimating the prevalence of type 1 diabetes in children and adolescents using electronic health records
Journal of the American Medical Informatics Association.
31(1):165-173
[DOI] 10.1093/jamia/ocad194.
[PMID] 37812771.
2022
A machine learning approach identifies modulators of heart failure hospitalization prevention among patients with type 2 diabetes: A revisit to the ACCORD trial.
Journal of diabetes and its complications.
36(9)
[DOI] 10.1016/j.jdiacomp.2022.108287.
[PMID] 36007486.
2022
A National Catalog of Mapped Short-Form Six-Dimension Utility Scores for Chronic Conditions in the United States From 2010 to 2015.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
25(8):1328-1335
[DOI] 10.1016/j.jval.2022.02.011.
[PMID] 35367137.
2022
Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US.
Diabetes therapy : research, treatment and education of diabetes and related disorders.
13(9):1659-1670
[DOI] 10.1007/s13300-022-01300-5.
[PMID] 35930188.
2022
Economic Evaluation of the $35 Insulin Copay Cap Policy in Medicare and Its Implication for Future Interventions
Diabetes Care.
45(11):e161-e162
[DOI] 10.2337/dc22-1230.
[PMID] 36099174.
2022
Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study.
Journal of diabetes and its complications.
36(3)
[DOI] 10.1016/j.jdiacomp.2022.108132.
[PMID] 35101326.
2022
Growing global burden of type 1 diabetes needs multitiered precision public health interventions.
The lancet. Diabetes & endocrinology.
10(10):688-689
[DOI] 10.1016/S2213-8587(22)00257-1.
[PMID] 36113506.
2022
Lowering hemoglobin A1c level to less than 6.0% in people with type 2 diabetes may reduce major adverse cardiovascular events: a Bayesian’s narrative.
Current medical research and opinion.
38(11):1883-1884
[DOI] 10.1080/03007995.2022.2129234.
[PMID] 36164760.
2022
Newer glucose-lowering drugs and risk of dementia: A meta-analysis of cardiovascular outcome trials.
Journal of the American Geriatrics Society.
70(9):2719-2722
[DOI] 10.1111/jgs.17895.
[PMID] 35612586.
2022
Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes.
JAMA network open.
5(4)
[DOI] 10.1001/jamanetworkopen.2022.7705.
[PMID] 35435970.
2022
Predicting incident heart failure among patients with type 2 diabetes mellitus: TheDM‐CURErisk score
Diabetes, Obesity and Metabolism.
24(11):2203-2211
[DOI] 10.1111/dom.14806.
[PMID] 35801340.
2022
Projected Impact of the Medicare Part D Senior Savings Model on Diabetes-Related Health and Economic Outcomes Among Insulin Users Covered by Medicare
Diabetes Care.
45(8):1814-1821
[DOI] 10.2337/dc21-2601.
[PMID] 35700384.
2022
Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes
Diabetes Care.
45(2):e32-e33
[DOI] 10.2337/dc21-1800.
2022
Syndromic Surveillance Systems for Mass Gatherings: A Scoping Review.
International journal of environmental research and public health.
19(8)
[DOI] 10.3390/ijerph19084673.
[PMID] 35457541.
2022
Using modern risk engines and machine learning/artificial intelligence to predict diabetes complications: A focus on the BRAVO model.
Journal of diabetes and its complications.
36(11)
[DOI] 10.1016/j.jdiacomp.2022.108316.
[PMID] 36201893.
2021
A varied approach to left ventricular assist device follow-up improves cost-effectiveness.
Current medical research and opinion.
37(9):1501-1505
[DOI] 10.1080/03007995.2021.1948395.
[PMID] 34181489.
2021
Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study.
Journal of diabetes and its complications.
35(9)
[DOI] 10.1016/j.jdiacomp.2021.107972.
[PMID] 34247911.
2021
Comparing the downstream costs and healthcare utilization associated with the use of low-dose computed tomography (LDCT) in lung cancer screening in patients with and without alzheimer’s disease and related dementias (ADRD).
Current medical research and opinion.
37(10):1731-1737
[DOI] 10.1080/03007995.2021.1953972.
[PMID] 34252317.
2021
Cost-Effectiveness of the New 2018 American College of Physicians Glycemic Control Guidance Statements Among US Adults With Type 2 Diabetes.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
24(2):227-235
[DOI] 10.1016/j.jval.2020.09.010.
[PMID] 33518029.
2021
The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010-2018.
Current medical research and opinion.
37(11):1875-1880
[DOI] 10.1080/03007995.2021.1971181.
[PMID] 34429001.
2021
Trends in Total and Out-of-pocket Payments for Insulin Among Privately Insured U.S. Adults With Diabetes From 2005 to 2018
Diabetes Care.
44(10):e180-e182
[DOI] 10.2337/dc20-2529.
2021
Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among U.S. Adults With Large-Employer Private Health Insurance From 2005 to 2018
Diabetes Care.
44(4):925-934
[DOI] 10.2337/dc20-2871.
2020
Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care 2019;42:2298–2306
Diabetes Care.
43(2):e25-e25
[DOI] 10.2337/dc19-1891.
[PMID] 31959647.
2020
Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005–2007 and 2015–2017
Diabetes Care.
43(10):2396-2402
[DOI] 10.2337/dc19-2273.
[PMID] 32737138.
2020
Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study
Diabetes Care.
43(11):2847-2852
[DOI] 10.2337/dc20-0465.
[PMID] 32887705.
2020
Statin Use for Atherosclerotic Cardiovascular Disease Prevention Among Sexual Minority Adults.
Journal of the American Heart Association.
9(24)
[DOI] 10.1161/JAHA.120.018233.
[PMID] 33317368.
2020
Trajectories of Short Physical Performance Battery Are Strongly Associated with Future Major Mobility Disability: Results from the LIFE Study.
Journal of clinical medicine.
9(8)
[DOI] 10.3390/jcm9082332.
[PMID] 32707877.
2020
Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors
Diabetes Care.
43(7):1530-1536
[DOI] 10.2337/dc20-0227.
[PMID] 32345650.
2019
Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
22(12):1402-1409
[DOI] 10.1016/j.jval.2019.08.007.
[PMID] 31806197.
2019
Influence of Diabetes Complications on HbA1c Treatment Goals Among Older U.S. Adults: A Cost-effectiveness Analysis
Diabetes Care.
42(11):2136-2142
[DOI] 10.2337/dc19-0381.
Grants
Sep 2022
– Dec 2022
Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) for Improving Disease Management
Role: Principal Investigator
Funding: TULANE UNIV.
via CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2022
– Dec 2022
Assessing Barriers and Facilitators for Participating Structured Lifestyle Intervention and Its Real-world Effectiveness and Cost-effectiveness among US Veterans
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2020
ACTIVE
Using Real-world Data to Assess the Burden of Diabetes in Children and Adolescents in Florida
Role: Project Manager
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2020
– Sep 2022
Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) for Improving Disease Management
Role: Principal Investigator
Funding: TULANE UNIV.
via CTRS FOR DISEASE CONTROL AND PREVENTION
Jul 2020
– Jul 2021
Simulating Long-Term Outcomes for iGlarlixi using BRAVO Diabetes Model
Role: Principal Investigator
Funding: TULANE UNIV.
via SANOFI
Jun 2020
– Jun 2022
CDC IPA – Assignment Agreement 20IPA2008335DPG
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Contact Details
Phones:
- Business:
- (352) 294-8323
Emails:
- Business:
- hui.shao@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100496
GAINESVILLE FL 32610 - Business Street:
-
PO Box 100496
GAINESVILLE FL 32610
Recent news
Dr. Hui Shao elected Director of Academics for the China Health Policy and Management Society
As Director of Academics, Shao will organize CHPAMS’ annual conference and develop two webinar series focused on introducing advanced methods in health economics and health services research and issues-driven research…
Dr. Hui Shao earns Early Career Award from CDC
The Centers for Disease Control and Prevention, or CDC, Health Economics Research Group bestowed Hui Shao, M.D., Ph.D., an assistant professor of pharmaceutical outcomes and policy, with the Kaafee Billah…